Affy Sees Opportunities for New 384-Sample Axiom Genotyping Product in Ag, Disease Research Markets | GenomeWeb

Affymetrix representatives recently provided an update on the firm's forthcoming 384-sample genotyping product and advocated its use in both agricultural biotechnology and human disease research.

"The 384 format is ideally suited for genomic selection or marker selection, where you have to do high-throughput [analyses on the order of] 3,000 samples per week," said Shantanu Kaushikkar, head of strategic marketing for agrigenomics at Affy. "It's the next step for ag researchers."

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Cell this week: proteomic consequences of genomic changes in ovarian cancer, Human SRMAtlas, and more.

At Nature, John Wilbanks and Eric Topol call for openness in health data.

Law.com predicts that genomic and genetic testing will become common in toxic tort cases.

A Pew Research Center report finds that most Americans are wary of using technologies like gene editing to enhance human abilities.